|
14 Jun 2022 |
Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates
|
|
13 Jun 2022 |
ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline
|
|
10 Jun 2022 |
Degron Therapeutics Raises $22M Series A Financing to Accelerate Growth and Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform
|
|
08 Jun 2022 |
Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer
|
|
06 Jun 2022 |
Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
|
|
03 Jun 2022 |
Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
|
|
03 Jun 2022 |
Boehringer Ingelheim enters global licensing agreement to develop and commercialize innovative antibodies from A*STAR for targeted cancer therapies
|
|
03 Jun 2022 |
Proxygen Announces Strategic Collaboration with Merck to Develop Molecular Glue Degraders
|
|
02 Jun 2022 |
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)
|
|
02 Jun 2022 |
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
|
|
01 Jun 2022 |
Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology
|
|
31 May 2022 |
GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
|
|
24 May 2022 |
KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses
|
|
23 May 2022 |
Innoviva to Acquire Entasis Therapeutics
|
|
20 May 2022 |
Cadherin 17-Targeted Novel Drug Modalities: a Target and Pipeline Review
|
|
19 May 2022 |
Almirall and Evotec enter into a multi-target alliance in Medical Dermatology
|
|
18 May 2022 |
BGF, Scottish National Investment Bank and Scottish Enterprise join forces to invest £8m in Aberdeen biologics company Elasmogen
|
|
17 May 2022 |
LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2
|
|
16 May 2022 |
AbbVie and Cugene Announce Collaboration in Autoimmune Diseases
|
|
16 May 2022 |
Remix Therapeutics Closes $70 Million Series B Financing
|
|
13 May 2022 |
BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology
|
|
12 May 2022 |
Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation
|
|
11 May 2022 |
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
|
|
10 May 2022 |
Pfizer to Acquire Biohaven Pharmaceuticals
|
|
09 May 2022 |
Twist Bioscience Enters into Research, Exclusive Option and License Agreement with Astellas for Antibodies to Reduce Tumor Microenvironment-Mediated Immunosuppression
|
